5e905c9e1cf82.pdf
DOI:
Mavjud emas
1. Bromuro C., Romano M.,Chiani P., Berti F., Tontini M., Proietti D., Mori E., Torosantucci A., Constantino P., Rappuoli R., Cassone A. Beta- glucan –CRM197 conjugates as candidates antifungal vaccines. Vaccine, 2010, vol.28, no. 14, pp.2615-2623. 2. Bryant K.A., Block S.L., Baker S.A., Gruber W.C., Scott D.A., PCV13 Infant Study Group. Safety and immunogenicity of a 13- valent pneumococcal conjugate vaccine. Pediatrics, 2010, vol. 125, no. 5, pp. 866- 875. 3. Dagan R., Poolman J., Siegrist C.A. Glycoconjugate vaccines and immune interference: a review. Vaccine, 2010,vol. 28, no. 34,pp. 5513-5523. 4. Hwang K.W. Haemophilus influenza type b (Hib) vaccine and its carrier proteins. Arch. Pharm. Res., 2010, vol. 33, no. 6, pp. 793-795. 5. Kuo Y.C., Chung C.Y., Transcytosis of CRM197- grafted polybutylcyanoaacrylate nanoparticles far delivering zidovudine across human brain- microvascular endothelial cells. Colloids Surf. B:Biointerfaces, 2012, vol. 91, pp.242-249. 6. Leka O., Vallese F., Pirazzini M., Berto P., Montecucco C., Zanotti G. Diphteria toxin conformational switching at acidic pH. FEBS J.,2014, vol. 281, no.9, pp. 2115-2122. 7. Park K. Targeted delivery to monocytes.J. Control. Release, 2012, vol. 158, no. l.p.l.